In its upcoming report, Gilead Sciences (GILD) is predicted by Wall Street analysts to post quarterly earnings of $1.83 per share, reflecting a decline of 3.7% compared to the same period last year.

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching dealmaking from a “position of strength” as a more mature biopharma, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based ...

With so many lip products on the market, choosing just one feels as complicated as choosing the right boyfriend — and honestly, the tradeoffs are eerily similar. Do I want something to stay with me ...

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...

Logos of Gilead at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov (Reuters) -Gilead Sciences said on Friday its ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.

On Oct. 6, Gilead Sciences GILD announced a settlement with three generic manufacturers, securing an agreement for them not to launch a generic version of the firm’s HIV drug Biktarvy in the United ...

Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...

Gilead Sciences has bolted another asset onto the virology engine that powers the company, paying (PDF) Health Hope Pharma $10 million upfront for global rights to a candidate in a limited set of ...

Gilead Sciences broke ground on its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters in California. This milestone ...